BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28030635)

  • 1. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
    Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
    PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value.
    Rosager AM; Sørensen MD; Dahlrot RH; Hansen S; Schonberg DL; Rich JN; Lathia JD; Kristensen BW
    PLoS One; 2017; 12(8):e0182954. PubMed ID: 28837569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
    Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
    Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
    Abd El-Hafez A; Ismail Hany HSED
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 identifies perivascular niches in grade II-IV astrocytomas.
    Christensen K; Schrøder HD; Kristensen BW
    J Neurooncol; 2008 Nov; 90(2):157-70. PubMed ID: 18612800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
    Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
    PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
    Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
    Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors.
    Lange F; Kaemmerer D; Behnke-Mursch J; Brück W; Schulz S; Lupp A
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1227-1237. PubMed ID: 29696364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
    Aaberg-Jessen C; Sørensen MD; Matos ALSA; Moreira JM; Brünner N; Knudsen A; Kristensen BW
    BMC Cancer; 2018 Mar; 18(1):270. PubMed ID: 29523123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic value of JAM-A in gliomas.
    Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
    J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology.
    Babu R; Bagley JH; Park JG; Friedman AH; Adamson C
    J Neurosurg; 2013 Aug; 119(2):434-41. PubMed ID: 23662821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
    Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
    Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
    Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
    Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
    Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
    Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression patterns of Wnt signaling component, secreted frizzled‑related protein 3 in astrocytoma and glioblastoma.
    Pećina-Šlaus N; Kafka A; Varošanec AM; Marković L; Krsnik Ž; Njirić N; Mrak G
    Mol Med Rep; 2016 May; 13(5):4245-51. PubMed ID: 27035837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of neuronal markers, NFP and GFAP, in malignant astrocytoma.
    Hashemi F; Naderian M; Kadivar M; Nilipour Y; Gheytanchi E
    Asian Pac J Cancer Prev; 2014; 15(15):6315-9. PubMed ID: 25124617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.